Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Earnings Results, Misses Expectations By $0.13 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13), Zacks reports. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA traded up $0.05 during trading hours on Wednesday, reaching $7.44. The company had a trading volume of 1,667,480 shares, compared to its average volume of 2,208,623. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $9.94. The firm has a market cap of $447.37 million, a PE ratio of -1.99 and a beta of 0.65. The business’s 50 day moving average price is $7.62 and its 200-day moving average price is $6.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, CMO Joakim Wijkstrom sold 30,800 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $254,716.00. Following the completion of the transaction, the chief marketing officer directly owned 333,469 shares of the company’s stock, valued at approximately $2,757,788.63. The trade was a 8.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.17, for a total value of $1,276,439.95. Following the completion of the transaction, the chief executive officer directly owned 2,704,496 shares of the company’s stock, valued at $22,095,732.32. The trade was a 5.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 314,342 shares of company stock valued at $2,583,985 in the last three months. 8.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Panagora Asset Management Inc. raised its stake in shares of Vanda Pharmaceuticals by 3.4% during the 4th quarter. Panagora Asset Management Inc. now owns 118,987 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 3,928 shares during the period. Jane Street Group LLC raised its stake in shares of Vanda Pharmaceuticals by 6.1% during the 2nd quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 4,533 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Vanda Pharmaceuticals by 20.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 35,283 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 6,027 shares during the period. Finally, Hsbc Holdings PLC raised its stake in shares of Vanda Pharmaceuticals by 17.6% during the 2nd quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 9,960 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th. Zacks Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. HC Wainwright lifted their target price on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Finally, Truist Financial assumed coverage on Vanda Pharmaceuticals in a report on Thursday, March 5th. They issued a “buy” rating and a $18.00 price target for the company. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.90.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.